Psychedelics
International Regulatory Developments For Key Psychedelics
Stephen Wright breaks down the lengthy process of getting a psychedelic medicine approved in the US.
Most Ayahuasca Users Vomit, Study Finds
Acute physical health adverse effects were reported by 69.9% of the study's participants.
The Dark Side of Psychedelic Trials
Dr. Markus Roggen, president and chief science officer of Vancouver-based Delic Labs, delves into the less favorable side of psychedelic research.
Colorado Votes to Decriminalize Most Psychedelics and Regulate Psilocybin Therapy
Once enacted, the proposal will give any adult in the state, aged 21 and over, the legal right to possess, use, cultivate and share psilocybin, ibogaine, mescaline (not derived from peyote), DMT, and psilocyn without fear of arrest.
Microdosing LSD Boosts the Brain’s Reward System, Study Finds
A new study has found that a single microdose of LSD can increase brain activity related to its reward system.
Psilocybin and Psychotherapy Relieve Treatment-Resistant Depression in Largest Clinical Trial to Date
The largest study to date testing the ability of the psychedelic compound psilocybin to treat a psychiatric disorder has shown that the mushroom-derived drug, delivered in combination with integrative psychotherapy sessions, significantly reduced participants’ depression as compared to a placebo after three weeks.
Synthetic Psychedelic Compounds May Treat Depression Without the Trip, Study Suggests
Scientists have developed a new compound which interacts with the same therapeutic targets in the brain as psychedelic drugs, producing the same long-lasting antidepressant and antianxiety effects but without the psychedelic high.
Alberta to Regulate Psychedelic-Assisted Therapy
Alberta will become the first province in Canada to regulate psychedelic-assisted therapy.
Psychedelic Drugs: How to Tell Good Research From Bad
James Rucker, a consultant psychiatrist at King's College London, breaks down the good psychedelic research from the bad. via the Conversation.
